Nemaura Medical to Present at the Access to Giving Virtual Investor Conference on July 13, 2021

Rhea-AI Summary

Nemaura Medical (Nasdaq: NMRD) announced a corporate overview presentation by CEO Faz Chowdhury, Ph.D. at the Access to Giving Virtual Investor Conference, scheduled for July 13, 2021, at 1:00pm ET.

The company is focused on non-invasive wearable diagnostic devices, such as sugarBEAT®, a glucose monitor approved in the EU. Nemaura is also targeting the substantial global diabetes market projected to reach $59 billion by 2025. For more details, investors can register for the conference.

Loughborough, England, July 12, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that Chief Executive Officer Faz Chowdhury, Ph.D. will present a corporate overview at the Access to Giving Virtual Investor Conference being held July 13 – 15, 2021.

Dr. Chowdhury will deliver his corporate presentation on July 13 at 1:00pm ET.

To receive additional information, request an invitation or to schedule a one-on-one meeting, please email angie.goertz@issuerdirect.com.

Investors can register here.

About Nemaura Medical, Inc.

Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT^® and proBEAT^™. sugarBEAT^®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT^® to the U.S. FDA. proBEAT^™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT^®diabetes program.

The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

For more information, please visit www.NemauraMedical.com.

Contact:
Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com

FAQ

What is the date and time of Nemaura Medical's presentation at the Access to Giving Virtual Investor Conference?

Nemaura Medical's presentation by CEO Faz Chowdhury is scheduled for July 13, 2021, at 1:00pm ET.

What is Nemaura Medical's focus in the healthcare market?

Nemaura Medical specializes in developing non-invasive wearable diagnostic devices and personalized lifestyle coaching programs.

What products does Nemaura Medical currently offer?

Nemaura Medical offers sugarBEAT®, a continuous glucose monitor, and proBEAT™, a digital health service.

How large is the global market for Type 2 diabetes and pre-diabetes?

The global Type 2 diabetes market is expected to reach nearly $59 billion by 2025, while the pre-diabetic market exceeds $50 billion.

How can investors register for the Access to Giving Virtual Investor Conference?

Investors can register for the Access to Giving Virtual Investor Conference through the provided links in the press release.